{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:50:15Z","timestamp":1781574615724,"version":"3.54.5"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"ANRS-PREVENIR study"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The potential preventive efficacy of tenofovir\/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar in PrEP users and in a matched population-based cohort, suggesting that tenofovir\/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.<\/jats:p>","DOI":"10.1093\/ofid\/ofac188","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T17:41:59Z","timestamp":1649785319000},"source":"Crossref","is-referenced-by-count":7,"title":["Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir\/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts"],"prefix":"10.1093","volume":"9","author":[{"given":"Constance","family":"Delaugerre","sequence":"first","affiliation":[{"name":"Service de Virologie, H\u00f4pital Saint Louis, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris , France"},{"name":"Universit\u00e9 de Paris, Inserm , U944, Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Maylin","sequence":"additional","affiliation":[{"name":"Service de Virologie, H\u00f4pital Saint Louis, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Minier","sequence":"additional","affiliation":[{"name":"Service de Virologie, H\u00f4pital Saint Louis, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Gabassi","sequence":"additional","affiliation":[{"name":"Service de Virologie, H\u00f4pital Saint Louis, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Genin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"Beniguel","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Service de Maladies infectieuses, H\u00f4pital Bichat, Assistance Publique\u2013H\u00f4pitaux de Paris , Infection, Antimicrobials, Modelling, Evolution, Inserm, Universit\u00e9 mixte de recherche 1137, Universit\u00e9 de Paris, Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[{"name":"Unit\u00e9 des Virus Emergents, Universit\u00e9 Aix Marseille , Institut de recherche pour le d\u00e9veloppement 190, Inserm U1207, Marseille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayssam","family":"El Mouhebb","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-7918","authenticated-orcid":false,"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"},{"name":"D\u00e9partement de Sant\u00e9 Publique, H\u00f4pital Saint-Antoine, Assistance Publique\u2013H\u00f4pitaux de Paris, \u00a0 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Inserm , U944, Paris , France"},{"name":"Service de Maladies Infectieuses, H\u00f4pital Saint Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, \u00a0 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the PREVENIR and SAPRIS-Sero Study Groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"2022073009485359500_ofac188-B1","doi-asserted-by":"crossref","first-page":"104857","DOI":"10.1016\/j.antiviral.2020.104857","article-title":"A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19","volume":"180","author":"Jockusch","year":"2020","journal-title":"Antiviral Res"},{"key":"2022073009485359500_ofac188-B2","first-page":"3204","article-title":"SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective","volume":"39","author":"Elfiky","year":"2021","journal-title":"J Biomol Struct Dyn"},{"key":"2022073009485359500_ofac188-B3","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01114-20","article-title":"Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets","volume":"11","author":"Park","year":"2020","journal-title":"mBio"},{"key":"2022073009485359500_ofac188-B4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7326\/M20-3689","article-title":"Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study","volume":"173","author":"Del Amo","year":"2020","journal-title":"Ann Intern Med"},{"key":"2022073009485359500_ofac188-B5","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cmi.2021.06.023","article-title":"Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort","volume":"27","author":"Berenguer","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022073009485359500_ofac188-B6","doi-asserted-by":"crossref","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","article-title":"Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa","volume":"73","author":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022073009485359500_ofac188-B7","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa455","article-title":"Preventive efficacy of tenofovir\/emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-exposure prophylaxis users","volume":"7","author":"Ayerdi","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2022073009485359500_ofac188-B8","doi-asserted-by":"crossref","first-page":"100993","DOI":"10.1016\/j.eclinm.2021.100993","article-title":"Effect of tenofovir disoproxil fumarate and emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: a pilot, randomized, open-label phase 2 trial","volume":"38","author":"Parienti","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2022073009485359500_ofac188-B9","article-title":"Incidence of HIV infection with daily or on-demand oral PrEP with TDF\/FTC in France","author":"Molina","year":"2021"},{"key":"2022073009485359500_ofac188-B10","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/ije\/dyab110","article-title":"Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study","volume":"50","author":"Carrat","year":"2021","journal-title":"Int J Epidemiol"},{"key":"2022073009485359500_ofac188-B11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12879-021-05864-8","article-title":"Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study","volume":"21","author":"Carrat","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2022073009485359500_ofac188-B12","doi-asserted-by":"crossref","first-page":"104511","DOI":"10.1016\/j.jcv.2020.104511","article-title":"Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)","volume":"129","author":"Nicol","year":"2020","journal-title":"J Clin Virol"},{"key":"2022073009485359500_ofac188-B13","doi-asserted-by":"crossref","first-page":"e051711","DOI":"10.1136\/bmjopen-2021-051711","article-title":"Diabetes, obesity, hypertension and risk of severe COVID-19: a protocol for systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"BMJ Open"},{"key":"2022073009485359500_ofac188-B14","first-page":"137","article-title":"Tenofovir disoproxil fumarate and severity of COVID-19 in people with HIV infection. In: Abstracts of the 2022 Conference on Retroviruses and Opportunistic Infections","volume":"30","author":"Del Amo","year":"2022","journal-title":"Top Antiv Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac188\/43370866\/ofac188.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac188\/45028726\/ofac188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac188\/45028726\/ofac188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T09:49:26Z","timestamp":1659174566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac188\/6567517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac188","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,12]]},"article-number":"ofac188"}}